Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

By L. Peyrin-Biroulet, W. Sandborn, Bruce E. Sands, W. Reinisch, W. Bemelman, R. Bryant, G. D'Haens, I. Dotan, M. Dubinsky, B. Feagan and 28 more. American Journal of Gastroenterology, 2015

1,734 citations recorded by the source corpus.

Subfields: Epidemiology, Genetics, Neurology

View Paper: https://www.semanticscholar.org/paper/0330f1578dbff4f65ec7d5d6605c3c7adca6e422

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. L. Peyrin-Biroulet
2. J. Colombel
3. Ashwin N. Ananthakrishnan

In Genetics

1. L. Peyrin-Biroulet
2. J. Colombel
3. Ashwin N. Ananthakrishnan

Citations in the corpus

• Ulcerative colitis (2017, background): “There is, therefore, a push to redefine disease severity using composite criteria that incorporate (1) disease effect on patient symptoms, quality of life, and disability; (2) measureable inflammatory burden using objective markers of disease activity and extent; and (3) disease course, including st”
• ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment. (2019, background): “11,18 This has been extensively reported, although no large RCTs were dedicated to this issue.”
• ACG Clinical Guideline: Ulcerative Colitis in Adults (2019, background): “STRIDE proposed that these end points should be assessed at a minimum every 3 months during the active phase of disease (79).”